EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study

Ameya D Puranik, Indraja D Dev, Venkatesh Rangarajan, Yash Jain, Sukriti Patra, Nilendu C Purandare, Arpita Sahu, Amitkumar Choudhary, Kajari Bhattacharya, Tejpal Gupta, Abhishek Chatterjee, Archya Dasgupta und 14 weitere

Neuroradiology · 2025

DOI: 10.1007/s00234-024-03495-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroradiology, 2025. Verfasst von Ameya D Puranik und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha National University, Tata Memorial Hospital, Mumbai, India. ameya2812@gmail.com. Hauptthemen laut MEDLINE: Glioma, Neoplasm Recurrence, Local, Brain Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tata Memorial Hospital - TMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The clinico-radiological dilemma in post-treatment high-grade gliomas, between disease recurrence (TR) and treatment-related changes (TRC), still persists. FET (Fluoro-ethyl-tyrosine) PET has been extensively used as problem-solving modality for cases where MR imaging is inconclusive. We incorporated a systematic imaging and clinical follow-up algorithm in a multi-disciplinary clinic (MDC) setting to analyse our cohort of FET PET in post-treatment gliomas.

Methods

We retrospectively analyzed 171 patients of post-treatment grade III and IV glioma with equivocal findings on MRI. 185–222 MBq of 18 F-FET was injected and dedicated static imaging of brain was performed at 20 min. TBR (Tumor to background ratio) was used as semi-quantitative parameter. Cutoff of 2.5 was used for image interpretation. Imaging findings were confirmed with histopathological diagnosis, wherever available or in a multidisciplinary joint clinic based on serial imaging.

Results

121 of 171 patients showed recurrent disease on FET PET, on follow up, 109 were confirmed with recurrence; 7 patients showed TRC, whereas 5 were treated with bevacizumab, with no further clinico-radiological deterioration, thus confirming TRC. 50 patients showed TRC on FET PET, on follow up on follow up, 40 were confirmed as true-negative. 10 patients who showed TBR less than 2.5 had confirmed TR on subsequent MR imaging. The overall sensitivity and specificity was 91.6 and 76.9% respectively, with a diagnostic accuracy of 87.13%.

Conclusion

There is potential for FET PET to be used along with MRI in the post treatment algorithm of high-grade glial tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaNeoplasm Recurrence, LocalBrain NeoplasmsPositron-Emission TomographyTyrosineHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedRadiopharmaceuticalsNeoplasm GradingMagnetic Resonance ImagingSensitivity and SpecificityDiagnosis, Differential

Stichwörter der Autor:innen

FET PETHigh grade gliomaMRIPost-treatment changesRecurrence

Substanzen

RadiopharmaceuticalsTyrosine(18F)fluoroethyltyrosine

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha National University, Tata Memorial Hospital, Mumbai, India. ameya2812@gmail.com.
  • Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha National University, Tata Memorial Hospital, Mumbai, India.
  • Department of Radiodiagnosis, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Mumbai, India.
  • Department of Radiation Oncology, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Mumbai, India.
  • Department of Neurosurgery, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Mumbai, India.
  • Department of Pathology, Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Mumbai, India.

Förderung

  • Tata Memorial Hospital - TMC

Zitieren

APA

Puranik, A. D., Dev, I. D., Rangarajan, V., Jain, Y., Patra, S., Purandare, N. C., Sahu, A., Choudhary, A., Bhattacharya, K., Gupta, T., Chatterjee, A., Dasgupta, A., Moiyadi, A., Shetty, P., Singh, V., Sridhar, E., Sahay, A., Shah, A., Menon, N., …, & Gopalakrishna, A. (2025). FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study. Neuroradiology. https://doi.org/10.1007/s00234-024-03495-9

Vancouver

Puranik AD, Dev ID, Rangarajan V, Jain Y, Patra S, Purandare NC, et al. FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study. Neuroradiology. 2025. doi:10.1007/s00234-024-03495-9

BibTeX
@article{Puranik2025,
  author = {Puranik, Ameya D and Dev, Indraja D and Rangarajan, Venkatesh and Jain, Yash and Patra, Sukriti and Purandare, Nilendu C and Sahu, Arpita and Choudhary, Amitkumar and Bhattacharya, Kajari and Gupta, Tejpal and Chatterjee, Abhishek and Dasgupta, Archya and Moiyadi, Aliasgar and Shetty, Prakash and Singh, Vikas and Sridhar, Epari and Sahay, Ayushi and Shah, Aekta and Menon, Nandini and Ghosh, Suchismita and Choudhury, Sayak and Shah, Sneha and Agrawal, Archi and Lakshminarayanan, N and Kumar, Amit and Gopalakrishna, Arjun},
  title = {FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study},
  journal = {Neuroradiology},
  year = {2025},
  doi = {10.1007/s00234-024-03495-9}
}
Kostenlos starten →